All In Biotech

Drug Trial Radar · NCT04794699

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

169

Actual

Start

Apr 14, 2021

Primary completion

Jan 7, 2027

Study completion Feb 4, 2027

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
First posted
Mar 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).

Conditions

  • Solid Tumor

Interventions

  • IDE397Drug

    IDE397 dosed orally

  • Sacituzumab govitecanDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting Toxicities (DLTs) of IDE397Time frame: 21 days following the first dose of IDE397
  2. Dose-limiting Toxicities (DLTs) of IDE397 in combination with sacituzumab govitecanTime frame: 21 - 28 days following the first dose of IDE397
  3. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397Time frame: Approximately 2 years
  4. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397 in combination with sacituzumab govitecanTime frame: Approximately 2 years
  5. To evaluate preliminary anti-tumor activity of IDE397 as monotherapy and in combination with sacituzumab govitecan-hziy in expansion armsTime frame: Approximately 2 years

Locations

37 sites in 7 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • Rockefeller Cancer Institute

    Little Rock, Arkansas

  • City of Hope

    Duarte, California

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Indiana University Health Hospital

    Indianapolis, Indiana

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Columbia University Medical Center - Herbert Irving Pavilion

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • LifeSpan - Brown University

    Providence, Rhode Island

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson

    Houston, Texas

  • Next Oncology

    San Antonio, Texas

  • Swedish Cancer Institute

    Seattle, Washington

  • The Kinghorn Cancer Centre, St Vincent's Health Network Sydney

    Darlinghurst, New South Wales, Australia

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, Australia

  • Centre Georges Francois LeClerc

    Dijon, France

  • Centre Eugène Marquis

    Rennes, France

  • Gustave Roussy

    Villejuif, France

  • Institut Bergonie

    Bordeaux, Bordeaux Cedex, France

  • Institut Claudius Regaud - IUCT-Oncopole

    Toulouse, Cedex 9, France

  • Hôpital Timone

    Marseille, Marseille, France

  • Universitaetsklinikum Hamburg-Eppendorf (UKE)

    Hamburg, Germany

  • Sevrance Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea

  • CHA University - Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea

  • Hospital Universitario 12 de Octubre (H12O)

    Madrid, Spain

  • START Madrid-HM - Centro Integral Oncológico Clara Campal (CIOCC)

    Madrid, Spain

  • NEXT Madrid, Universitary Hospital QuironSAlud

    Madrid, Spain

  • Instituto Valenciano de Oncología (IVO)

    Valencia, Spain

  • National Cheng Kung University Hospital

    Tainan, Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.